Recent Company News

• 09:36 AM ET Feb 18, 2026
  

  Transcript Intelligence: Recordati Q4 Earnings Guidance

• 09:36 AM ET Feb 18, 2026
  

  Transcript Intelligence: Recordati Q4 Earnings Themes

• 09:36 AM ET Feb 18, 2026
  

  Transcript Intelligence: Recordati Q4 Earnings Q&A

• 02:55 AM ET Feb 18, 2026
  

  StreetAccount Summary - European pre-market trading update

• 12:25 PM ET Feb 17, 2026
  

  Recordati reports preliminary FY25 revenue €2.62B vs FactSet €2.62B [10 est, €2.60-2.66B] (€47.34, 0.00)

• 02:02 AM ET Feb 12, 2026
  

  Recordati upgraded to equal weight from underweight at Barclays (€47.48, 0.00)

• 01:27 AM ET Feb 03, 2026
  

  Recordati upgraded to buy from hold at Kepler Cheuvreux (€46.78, 0.00)

• 05:27 PM ET Jan 29, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 05:03 PM ET Jan 29, 2026
  

  Moderna announces strategic collaboration with Recordati to globally commercialize mRNA-3927 ($46.86, 0.00)

• 07:18 AM ET Jan 13, 2026
  

  Recordati's ISTURISA now available in Canada for treatment of Cushing's disease (€49.02, -0.76)